Hangzhou Changchuan Technology (300604) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
3 Jun, 2026Executive summary
Revenue for Q1 2025 reached ¥815.25 million, up 45.74% year-over-year, driven by strong sales demand.
Net profit attributable to shareholders was ¥111.00 million, a surge of 2,623.82% compared to the same quarter last year.
Excluding non-recurring items, net profit was ¥45.68 million, up 2,709.60% year-over-year.
Significant improvement in operating cash flow, turning positive to ¥121.04 million from a negative ¥240.29 million last year.
Financial highlights
Gross margin improved as revenue growth outpaced cost increases; operating costs rose 51.66% while revenue grew 45.74%.
Basic and diluted EPS were both ¥0.18, up from ¥0.01 in Q1 2024.
Total assets increased 6.99% from year-end 2024 to ¥7.76 billion.
Shareholders’ equity rose 5.17% to ¥3.46 billion.
Non-recurring gains included government subsidies and investment income from the acquisition of a controlling stake in Yuanlichuang.
Outlook and guidance
Management attributes growth to robust market demand and effective cost control.
Continued investment in R&D and expansion expected to support future growth.
Latest events from Hangzhou Changchuan Technology
- 2024 revenue and profit soared, fueled by R&D and market expansion, despite margin pressure.300604
Q4 20243 Jun 2026 - H1 revenue and net profit soared, with strong R&D and market expansion fueling growth.300604
Q2 20243 Jun 2026 - Revenue and net profit soared in Q3 2024, fueled by market recovery and strong sales.300604
Q3 20243 Jun 2026 - H1 2025 revenue and profit surged, fueled by innovation and manufacturing expansion.300604
Q2 20253 Jun 2026 - Net profit soared 190.42% on 45.31% revenue growth, with strong R&D and global expansion.300604
Q4 20253 Jun 2026 - Q3 2025 net profit soared 208% year-over-year on 60% revenue growth.300604
Q3 20253 Jun 2026 - Revenue and net profit surged in Q1 2026, but operating cash flow turned negative.300604
Q1 20263 Jun 2026